CYP2D6 and pharmacogenomics: Where does future research need to focus? Part 2: Clinical aspects

Pharmacogenomics

Volumn 15, Issue 8, 2014, Pages 1055-1058

  Leeder, J Steven ^a   Gaedigk, Andrea ^a  

^a UNIVERSITY OF MISSOURI KANSAS CITY SCHOOL OF MEDICINE   (United States)

Author keywords

clinical implementation; CPIC; CYP2D6; cytochrome P450; drug metabolizing enzymes; genetic variation; pharmacogenetics

Indexed keywords

ATOMOXETINE; BIOLOGICAL MARKER; CITALOPRAM; CYTOCHROME P450 2D6; ENDOXIFEN; ESCITALOPRAM; PIMOZIDE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TAMOXIFEN; TRICYCLIC ANTIDEPRESSANT AGENT;

ALLELE; BRAIN FUNCTION; CLINICAL PRACTICE; CYP2D6 GENE; DRUG CLEARANCE; DRUG EXPOSURE; DRUG LABELING; DRUG RESPONSE; EVIDENCE BASED PRACTICE; FOOD AND DRUG ADMINISTRATION; GENE EXPRESSION; GENE FUNCTION; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; HEREDITY; HUMAN; IN VIVO STUDY; MEDICAL RESEARCH; MENTAL DISEASE; METABOLOMICS; NEUROIMAGING; PHARMACOGENOMICS; PHENOTYPE; REVIEW; UNITED STATES; GENETICS; PHARMACOGENETICS;

CYTOCHROME P-450 CYP2D6; GENOTYPE; HUMANS; PHARMACOGENETICS;

EID: 84905445870     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.14.27     Document Type: Review

References (22)

1. Gaedigk A, Leeder JS. CYP2D6 and pharmacogenomics: where does future research need to focus? Part 1: technical aspects. Pharmacogenomics 15(4), 407-410 (2014).
2. US FDA. Table of Pharmacogenomics Biomarkers in Drug Labeling. www.fda.gov/Drugs/ScienceResearch/ResearchAreas/ Pharmacogenetics/ucm083378.htm
3. Pharmacogenomics Knowledge Base: PharmGKB. FDA label for aripiprazole and CYP2D6. www.pharmgkb.org/label/PA166104839
4. Pharmacogenomics Knowledge Base: PharmGKB. CPIC pairs (see PGx on FDA label). www.pharmgkb.org/cpic/pairs
5. Zhou S-F. Polymorphism of human cytochrome P450 2D6 and its clinical significance: part I. Clin. Pharmacokin. 48, 689-723 (2009).
6. Zhou S-F. Polymorphism of human cytochrome P450 2D6 and its clinical significance: part II. Clin. Pharmacokin. 48, 761-804 (2009).
7. Kirchheiner J, Nickchen K, Bauer M et al. Pharmacogenetics of antidepresants and antipsychotics: the contribution of allelic variants to the phenotype of drug response. Mol. Psychiatr. 9, 442-473 (2004).
8. Stingl JC, Brockmöller J, Viviani R. Genetic variability of drug-metabolizing enzymes: the dual impact on psychiatric therapy and regulation of brain function. Mol. Psychiatr. 18, 273-287 (2013).
9. Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group. Recommendations from the EGAPP Working Group: testing for cytochrome P450 polymorphisms in adults with nonpsychotic depression treated with selective serotonin reuptake inhibitors. Genet. Med. 9, 819-825 (2007).
10. Thakur M, Grossman I, McCrory DC et al. Review of evidence for genetic testing for CYP450 polymorphisms in management of patients with nonpsychotic depression with selective serotonin reuptake inhibitors. Genet. Med. 9, 826-835 (2007).
11. Grossman I, Sullivan PF, Walley N et al. Genetic determinants of variable metabolism have little impact on the clinical use of leading antipsychotics in the CATIE study. Genet. Med. 10, 720-729 (2008).
12. Holmes MV, Shah T, Vickery C, Smeeth L, Hingorani AD, Casas JP. Fulfilling the promise of personalized medicine? Systematic review and field synopsis of pharmacogenetic studies. PLoS ONE 4(12), e7960 (2009).
13. Sauer J-M, Ring BJ, Witcher JW. Clinical pharmacokinetics of atomoxetine. Clin. Pharmacokinet. 44, 571-590 (2005).
14. Irvin Jr WJ, Walko CM, Weck KE et al. Genotype-guided tamoxifen dosing increases active metabolite exposure in women with reduced CYP2D6 metabolism: a multicenter study. J. Clin. Oncol. 29, 3232-3239 (2011).
15. Hiemke C, Baumann P, Bergemann N et al. AGNP consensus guidelines for therapeutic drug monitoring in psychiatry: update 2011. Pharmacopsychiatry 44, 195-235 (2011).
16. Rogers HL, Bhattaram A, Zineh I et al. CYP2D6 genotype information to guide pimozide treatment in adult and pediatric patients: basis for the US Food and Drug Administration's new dosing recommendations. J. Clin. Psychiatry 73, 1187-1190 (2012).
17. Cheng J, Zhen Y, Miksys S et al. Potential role of CYP2D6 in the central nervous system. Xenobiotica 43, 973-984 (2013).
18. Kirchheiner J, Seeringer A, Godoy AL et al. CYP2D6 in the brain: genotype effects on resting brain perfusion. Mol. Psychiatr. 16, 333-341 (2011).
19. Stingl JC, Esslinger C, Tost H et al. Genetic variation in CYP2D6 impacts neural activation during cognitive tasks in humans. Neuroimage 59, 2818-2823 (2011).
20. Ji Y, Hebbring S, Zhu H et al. Glycine and a glycine dehydrogenase (GLDC) SNP as citalopram/escitalopram response biomarkers in depression: pharmacometabolomics-informed pharmacogenomics. Clin. Pharmacol. Ther. 89, 97-104 (2011).
21. Kaddurah-Daouk R, Boyle SH, Matson W et al. Pretreatment metabotype as a predictor of response to sertraline or placebo in depressed outpatients: a proof of concept. Transl. Psychiatry 1, e26 (2011).
22. Province MA, Goetz MP, Brauch H et al. CYP2D6 genotype and adjuvant tamoxifen: meta-analysis of heterogeneous study populations. Clin. Pharmacol. Ther. 95, 216-277 (2014).